Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREP-ANCA
NCT07451847Phase 4Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2026
- Primary completion
- Feb 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Survival without relapse at 24 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NCT07451847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07451847.